PL3919491T3 - Inhibitor akt - Google Patents
Inhibitor aktInfo
- Publication number
- PL3919491T3 PL3919491T3 PL20748221.7T PL20748221T PL3919491T3 PL 3919491 T3 PL3919491 T3 PL 3919491T3 PL 20748221 T PL20748221 T PL 20748221T PL 3919491 T3 PL3919491 T3 PL 3919491T3
- Authority
- PL
- Poland
- Prior art keywords
- akt inhibitor
- akt
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910084801 | 2019-01-29 | ||
| PCT/CN2020/073798 WO2020156437A1 (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3919491T3 true PL3919491T3 (pl) | 2025-10-20 |
Family
ID=71841634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20748221.7T PL3919491T3 (pl) | 2019-01-29 | 2020-01-22 | Inhibitor akt |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220144821A1 (pl) |
| EP (1) | EP3919491B1 (pl) |
| JP (2) | JP7617005B2 (pl) |
| CN (2) | CN117964620A (pl) |
| AU (1) | AU2020214258B2 (pl) |
| CA (1) | CA3127884A1 (pl) |
| ES (1) | ES3037595T3 (pl) |
| PL (1) | PL3919491T3 (pl) |
| WO (1) | WO2020156437A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3167999A1 (en) * | 2020-03-17 | 2021-09-23 | Xin Li | Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| AU2021314419B2 (en) * | 2020-07-22 | 2023-12-07 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
| CA3186565A1 (en) * | 2020-07-22 | 2022-01-27 | Lei Miao | Unit dosage composition of akt inhibitor |
| CA3186562A1 (en) * | 2020-07-22 | 2022-01-27 | Jian Wu | Salt and crystal form of dihydropyrido[2,3-d]pyrimidine derivate |
| CN116478156A (zh) * | 2022-01-17 | 2023-07-25 | 南京正大天晴制药有限公司 | 一种akt抑制剂化合物的富马酸盐晶型及其制备方法 |
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| WO2024255883A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
| CN120157686A (zh) * | 2023-12-14 | 2025-06-17 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004293026B2 (en) * | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| DK2049500T3 (da) | 2006-07-06 | 2011-12-12 | Array Biopharma Inc | Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer |
| US20130065908A1 (en) * | 2009-12-07 | 2013-03-14 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| WO2008006025A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| WO2009089462A1 (en) * | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| KR101398268B1 (ko) * | 2009-10-23 | 2014-05-23 | 일라이 릴리 앤드 캄파니 | Ａｋｔ 억제제 |
| ES2807539T3 (es) | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| ES2620119T3 (es) * | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa |
| MX382891B (es) | 2014-09-05 | 2025-03-13 | Arqule Inc | Composiciones y métodos para tratar trastornos de proliferación. |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| CN108503645A (zh) | 2018-03-01 | 2018-09-07 | 山东大学 | 含氨甲基的哌嗪酮类化合物及其制备方法和应用 |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
-
2020
- 2020-01-22 PL PL20748221.7T patent/PL3919491T3/pl unknown
- 2020-01-22 AU AU2020214258A patent/AU2020214258B2/en active Active
- 2020-01-22 EP EP20748221.7A patent/EP3919491B1/en active Active
- 2020-01-22 US US17/426,047 patent/US20220144821A1/en active Pending
- 2020-01-22 WO PCT/CN2020/073798 patent/WO2020156437A1/zh not_active Ceased
- 2020-01-22 CN CN202410142331.2A patent/CN117964620A/zh active Pending
- 2020-01-22 ES ES20748221T patent/ES3037595T3/es active Active
- 2020-01-22 JP JP2021543533A patent/JP7617005B2/ja active Active
- 2020-01-22 CA CA3127884A patent/CA3127884A1/en active Pending
- 2020-01-22 CN CN202080005749.9A patent/CN113272304B/zh active Active
-
2024
- 2024-09-19 JP JP2024161770A patent/JP2024175091A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024175091A (ja) | 2024-12-17 |
| CN113272304A (zh) | 2021-08-17 |
| CA3127884A1 (en) | 2020-08-06 |
| ES3037595T3 (en) | 2025-10-03 |
| EP3919491A4 (en) | 2022-10-19 |
| CN113272304B (zh) | 2024-03-29 |
| CN117964620A (zh) | 2024-05-03 |
| JP7617005B2 (ja) | 2025-01-17 |
| EP3919491A1 (en) | 2021-12-08 |
| EP3919491C0 (en) | 2025-05-28 |
| EP3919491B1 (en) | 2025-05-28 |
| US20220144821A1 (en) | 2022-05-12 |
| JP2022517866A (ja) | 2022-03-10 |
| AU2020214258B2 (en) | 2025-08-28 |
| KR20210120054A (ko) | 2021-10-06 |
| WO2020156437A1 (zh) | 2020-08-06 |
| AU2020214258A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3919491T3 (pl) | Inhibitor akt | |
| IL287767A (en) | cdk inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL290087A (en) | inhibitory substances | |
| CA188849S (en) | Showerhead | |
| GB201905328D0 (en) | Inhibitor compounds | |
| CA195194S (en) | Can | |
| EP4025564A4 (en) | NITRIFICATION INHIBITORS | |
| CA188846S (en) | Showerhead | |
| EP4019048A4 (en) | ABCC11 INHIBITOR | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| EP4263533C0 (en) | Erap inhibitors | |
| HK40071165A (en) | Inhibiting usp19 | |
| HK40070698A (en) | Inhibiting usp36 | |
| CA195860S (en) | Showerhead | |
| EP4049722A4 (en) | PROLIFERATION INHIBITOR | |
| GB201905318D0 (en) | Inhibitor compounds | |
| CA190993S (en) | Showerhead | |
| CA190568S (en) | Showerhead | |
| CA190454S (en) | Showerhead | |
| CA190450S (en) | Showerhead | |
| CA190447S (en) | Showerhead | |
| CA190446S (en) | Showerhead |